CANCER TREATMENT DRUG

MEDICAMENT DESTINE AU TRAITEMENT DU CANCER

English Abstract

The invention relates to a cancer treatment drug containing two biological
plant active ingredients having a cytotoxic action and carcinolytic
properties, namely extracts from the plants Peganum Harmala L. and
Drakocephalum Kotshyi Boss.

French Abstract

L'invention concerne un médicament destiné au traitement du cancer et contenant deux principes actifs végétaux biologiques, notamment des extraits des plantes Peganum Harmala L. et Drakocephalum Kotshyi Boss, ayant une action cytotoxique et des propriétés carcinolytiques.

Claims

CLAIMS

1. A drug for cancer therapy characterised in that it contains two
biological vegetable active substances with cytotoxic action which thus have
cancer cell-destroying properties.
2. A drug as set forth in claim 1 characterised in that as active
substances having cancer cell-destroying properties it contains extracts
from the plants Peganum Harmala L. and Dracocephalum Kotshyi Boss.
3. A drug as set forth in claim 1 or claim 2 characterised in that it
contains about 24% Peganum Harmala L. and between about 3 and 4%
Dracocephalum Kotshyi Boss, with the balance fillers.
4. A drug as set forth in claim 3 characterised in that it contains
23.8% Peganum Harmala L. and 3.3% Dracocephalum Kotshyi Boss.


5

Description

.,
. CA 02276276 1999-06-28
G 60 127
PHARMACEUTICAL RESEARCH CENTER
Drug for cancer therapy
The invention concerns a drug for cancer therapy, which is founded on
a biological basis.
Cancer is an illness in which body cells grow uncontrolledly. Various
therapies are known for preventing or at least confining cell growth of that
kind. One of the therapies which is most frequently applied at the present
time is so-called chemotherapy which suffers from serious side effects
without however resulting in sustained successes.
Tests with biological cancer therapies alone have also hitherto not
afforded long-lasting successes because it was also hitherto not possible
for the cancer cells which are formed in the human body to be effectively
destroyed with those therapies.
The object of the present invention is to provide a drug or
pharmaceutical preparation which has anti-cancer or cytostatic effects) by
means of which cancer cells can be effectively destroyed or at least curbed.
In accordance with the invention that object is attained by a drug
having the features of claim 1.
Advantageous configurations and embodiments of the invention are the
subject-matter of the appendant claims.
The anti-cancer agent according to the invention is a drug which
contains two vegetable substances with cytotoxic action and which can be
administered orally and/or rectally and/or parenterally.
This combination anti-cancer preparation preferably contains extracts
of two plants, more specifically Peganum harmala L. and Dracocephalum
Kotshyi Boss which contain substances having a cancer-inhibiting action.
Plants of that kind are indigenous to Iran.
Phytochemical investigations of those plants confirm inter alia the
presence of active substance such as alkaloids, flavonoids, tannin,

CA 02276276 1999-06-28
saponins, steroids, proteins, lipids, carbohydrates, essential oils.
minerals, amino acids and so forth.
The constituents or ingredients of the plant extracts to be used in
accordance with the invention are firstly prepared in the form of alcoholic
and aqueous extracts or solutions. Granules are produced from the mixture
which is formed therefrom. The granules and extracts which are obtained in
that way are processed to form tablets or other medicinal forms of
presentation in order to administer them to patients.
The drug according to the invention has inter alia cytotoxic, anti
phlogistic, anti-inflammatory, analgesic, anti-bacterial and anti-viral
actions.
The biological anti-cancer agent according to the invention acts as a
mitosis inhibitor and intervenes with an inhibiting effect in the mitosis
phase in cell division of cancer-affected cells.
The biological anti-cancer agent according to the invention combines
after administration with the deoxyribonucleic acid (DNA) chain and thereby
prevents the formation of ribonucleic acid (RNA). In that way it interferes
with the amino acids of the cells which are affected by cancer and thus
prevents cancer cell growth.
The molecular building structure of the biological anti-cancer agent
or preparati on accordi ng to the i nventi on i s such that the agent functi
ons
as a physiological and body-compatible agent in the body.
It has been found that the drug or preparation according to the
invention gives rise to positive therapy effects in relation to various
cancer tumours, for example mammary carcinoma, carcinomas of the gastro
intestinal tract, brain tumours and the like.
A particular advantage of the invention is that the positive therapy
effect can be achieved in relation to cancer cells, without side effects of
any consequence.
In particular the drug or preparation according to the invention, upon
administration, does rot have any adverse side effects on the blood count
and the natural blood components.
2


CA 02276276 1999-06-28
The drug or preparation according to the invention can be administered
as a mono- and/or combination therapy preparation with other biosubstances
and anti-tumour agents which have been produced on a biological and/or
conventional basis.
The drug or preparation according to the invention has a synergistic
effect in combination with oral oxygen therapy, whereby the effect of the
anti-cancer action is increased.
It has been found that the agent or preparation according to the
invention has a relaxant and relief effect. in particular in regard to
smooth musculatures.
The drug or preparation according to the invention has
immunostimulating and immunomodulating actions. Those properties have been
investigated and confirmed in relation to animals whose immune systems were
crippled by dimethylbenzanthracene (DMBA) as a carcinogenic and
immunosuppressive agent. In those animals, after treatment with the
biological anti-cancer agent according to the invention, immunostimulation
and immunomodulation were noted and documented. Those positive effects on
the immune system of a human being have also been demonstrated.
It was also possible to demonstrate a reduction in tumour markers in
the case of cancer patients treated with the drug or preparation according
to the invention.
Pharmacodynamical investigations with the drug or preparation
according to the invention showed a lethal dose (LDso) of 657.5 mg/kg
bodyweight in the case of investigated mice.
Pharmacodynamical comparative investigations with other anti-tumour
agents such as Vincristin. Vinblastin and Chlorambucil showed that the drug
or preparation according to the invention has optimum compatibility while
the previously known cancer-treatment agents give rise to serious side
effects which did not occur when using the drug according to the invention.
The cancer-inhibiting action of the drug or preparation according to
the invention was confirmed and documented by various cell investigations
and effects on cancer cells in humans and apes.
3


CA 02276276 1999-06-28
The extract obtained and produced in accordance with the invention
from two specific plants and its fractions were allowed to act on cancer
cells and control cells. The progression of that effect was monitored
through an electron microscope. Ultra-structural damage to the cancer cells
was found. in comparison with healthy control cells.
In cl i ni cal studi es , when usi ng the agent accordi ng to the i nventi on
i n rel ati on to cancer pati ents , there was found i n part total remi ssi
on as
well as an increase in life expectancy and an improvement in quality of
life.
The invention is further described hereinafter by reference to a
practical embodiment of a cancer-inhibiting drug set out in table form.
Constituent mg/tablet


Peganum harmala L. 142.7 23.8


Dracocephalum K.B. 19.6 3.3


Sugar powder 15,7 2.6


Calcium carbonate 43.6 7.3


Polyvinyl pyrrolidone (PVP)12.5 2.0


Starch 166.5 27.g


Lactose 156.0 26.0


Carboxymethylcellulose (CMC)10.0 1.6


Microcrystalline cellulose 24.0 4.0
(MCC>


Aerosyl 9.4 1.6


600.0 mg 100.0


_ 4